162 related articles for article (PubMed ID: 10584682)
1. Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study.
Dentresangle C; Veyre L; Le Bars D; Pierre C; Lavenne F; Pollak P; Guerin J; Froment JC; Brousolle E
Mov Disord; 1999 Nov; 14(6):1025-30. PubMed ID: 10584682
[No Abstract] [Full Text] [Related]
2. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
3. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
4. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.
Antonini A; Schwarz J; Oertel WH; Beer HF; Madeja UD; Leenders KL
Neurology; 1994 Jul; 44(7):1325-9. PubMed ID: 8035939
[TBL] [Abstract][Full Text] [Related]
5. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status.
Sawle GV; Playford ED; Brooks DJ; Quinn N; Frackowiak RS
Brain; 1993 Aug; 116 ( Pt 4)():853-67. PubMed ID: 8353712
[TBL] [Abstract][Full Text] [Related]
6. Modulatory effects of L-DOPA on D2 dopamine receptors in rat striatum, measured using in vivo microdialysis and PET.
Opacka-Juffry J; Ashworth S; Ahier RG; Hume SP
J Neural Transm (Vienna); 1998; 105(4-5):349-64. PubMed ID: 9720967
[TBL] [Abstract][Full Text] [Related]
7. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
8. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET.
Linazasoro G; Obeso JA; Gómez JC; Martínez M; Antonini A; Leenders KL
Clin Neuropharmacol; 1999; 22(5):277-80. PubMed ID: 10516878
[TBL] [Abstract][Full Text] [Related]
9. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease.
Rinne JO; Laihinen A; Rinne UK; Någren K; Bergman J; Ruotsalainen U
Mov Disord; 1993 Apr; 8(2):134-8. PubMed ID: 8474478
[TBL] [Abstract][Full Text] [Related]
10. PET studies and motor complications in Parkinson's disease.
Brooks DJ
Trends Neurosci; 2000 Oct; 23(10 Suppl):S101-8. PubMed ID: 11052227
[TBL] [Abstract][Full Text] [Related]
11. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.
Antonini A; Leenders KL; Vontobel P; Maguire RP; Missimer J; Psylla M; Günther I
Brain; 1997 Dec; 120 ( Pt 12)():2187-95. PubMed ID: 9448574
[TBL] [Abstract][Full Text] [Related]
12. Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients.
Politis M; Sauerbier A; Loane C; Pavese N; Martin A; Corcoran B; Brooks DJ; Ray-Chaudhuri K; Piccini P
Mov Disord; 2017 Feb; 32(2):235-240. PubMed ID: 27859651
[TBL] [Abstract][Full Text] [Related]
13. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease.
Rinne JO; Laihinen A; Någren K; Bergman J; Solin O; Haaparanta M; Ruotsalainen U; Rinne UK
J Neurosci Res; 1990 Dec; 27(4):494-9. PubMed ID: 1981915
[TBL] [Abstract][Full Text] [Related]
14. IBZM-SPECT imaging in Parkinson's disease. Quantification of binding ratios from sequential SPECT measurements in patients and controls.
Cordes M; Hierholzer J; Schelosky L; Poewe W; Cordes I; Horowski R; Eichstaedt H; Schmidt D; Felix R
Adv Neurol; 1993; 60():525-8. PubMed ID: 8420183
[No Abstract] [Full Text] [Related]
15. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
[TBL] [Abstract][Full Text] [Related]
16. Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
Med Lett Drugs Ther; 2015 Aug; 57(1474):112. PubMed ID: 26218794
[No Abstract] [Full Text] [Related]
17. Downregulation of striatal dopamine D2 receptors in advanced Parkinson's disease contributes to the development of motor fluctuation.
Hwang WJ; Yao WJ; Wey SP; Shen LH; Ting G
Eur Neurol; 2002; 47(2):113-7. PubMed ID: 11844900
[TBL] [Abstract][Full Text] [Related]
18. Chronic subthalamic nucleus stimulation and striatal D2 dopamine receptors in Parkinson's disease--A [(11)C]-raclopride PET study.
Thobois S; Fraix V; Savasta M; Costes N; Pollak P; Mertens P; Koudsie A; Le Bars D; Benabid AL; Broussolle E
J Neurol; 2003 Oct; 250(10):1219-23. PubMed ID: 14586606
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Silver DE
Expert Rev Neurother; 2004 Jul; 4(4):589-99. PubMed ID: 15853578
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.
Kaasinen V; Ruottinen HM; Någren K; Lehikoinen P; Oikonen V; Rinne JO
J Nucl Med; 2000 Jan; 41(1):65-70. PubMed ID: 10647606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
